All In Biotech

Drug Trial Radar · NCT01217515

Diltiazem Hydrochloride Cream for Anal Fissure

A Randomised,Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Diltiazem Hydrochloride Cream in Subjects With Anal Fissure

Last checked: Nov 19, 2026Latest source record: Jul 17, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 465 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

465

Actual

Start

Oct 2010

Primary completion

Mar 2012

Study completion May 2012

Sponsor

Lead sponsor
S.L.A. Pharma AGIndustry
Sponsor type
Industry
First posted
Oct 8, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase III, multicentre, randomised, double blind, placebo-controlled study in subjects having anal fissure (AF) with AF-related pain. Subjects will undertake a 1-week screening period to provide baseline data and for assessment of eligibility. At the Baseline visit (Week 0), eligible subjects (having an average Numerical Rating Scale (NRS) score of \>4 for worst pain associated with or following defaecation) will be randomised on a 1:1:1 basis to one of the three treatment groups. Subjects will receive diltiazem hydrochloride 2% cream or diltiazem hydrochloride 4% cream or placebo cream. Study treatment will be applied in and around the anus, three times daily, for up to 8 weeks. Following the Week 0 Visit, subjects will be contacted by telephone during Week 1 to ensure adequate compliance with study treatment, to ensure that study drug is being tolerated and that any concomitant medications are used at a level consistent with that prior to randomisation. Subjects will return to the clinic for safety and efficacy assessments at Weeks 2, 4, and 8 and receive a follow-up telephone call at Week 12, following cessation of therapy. Concomitant laxatives and stool softeners will be permitted, as needed, during the entire study period (screening and treatment) to ensure that constipation or passage of hard stools does not confound evaluation or improvement of the condition. Fibre supplements will be allowed but should be continued at the baseline level. Instructions on the use of the Interactive Voice Response System (IVRS) diary will be issued to subjects to record fissure-related pain (NRS) and bowel symptoms daily during the 1-week screening period, to confirm eligibility and post-randomisation to record worst anal pain associated with or following defaecation (NRS) and daily overall AF-related pain (NRS). A record of the number of times the subject has defaecated, laxative and analgesic usage will also be made as well as the number of applications of study treatment, any changes to concurrent medications and any Adverse Events (AEs). In addition, at some or all study visits, subjects will record the Patient's Global Impression of Improvement (PGI-I) on a 7 point Likert scale, complete a Short Form 36 (SF-36) quality of life questionnaire and will undergo examination of their AF. Routine blood samples will be taken and the Skin Irritation Score (SIS) recorded for safety evaluations. Subjects may receive permitted medications for pain per Entry Criteria, but these should remain stable, where possible, up to the Week 8 Visit. Introduction of any new medication for AF will not be permitted unless the Investigator deems "rescue" intervention necessary. A subject will be deemed a treatment failure if rescue intervention is required and will have to be withdrawn from the study. Any subject leaving the study following randomisation for any reason will be asked to complete the Early Withdrawal Visit. This includes subjects who withdraw due to the development of AEs or intolerance, as well as subjects who require rescue intervention. These subjects will return for safety follow-up visits at their previously scheduled follow-up assessment appointments. If complete healing has occurred at the 2 or 4 Week visits, (i.e. prior to the end of the 8-week treatment period), subjects will be asked to continue applying the medication for the full 8 week course, up to the final assessment. Following the Week 8 visit (or Early Withdrawal Visit), subjects will be followed up for a further 4 weeks (following cessation of study medication) to note any AEs. All routine blood analyses (haematology and biochemistry) and plasma levels of diltiazem and of its principal metabolites will be analysed by central laboratories.

Conditions

  • Chronic Anal Fissure

Interventions

  • Diltiazem hydrochloride 4% creamDrug

    3 times daily

  • Diltiazem hydrochloride 2% creamDrug

    3 times daily

  • PlaceboOther

    3 times daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Average of Worst Anal Pain Associated With or Following Defaecation for Week 4 (for the 7 Treatment Days Immediately Preceding the Week 4 Visit).Time frame: 4 weeks

Locations

27 sites in 6 countries. Site status is shown where the registry gives one.

  • Vth MHAT

    Sofia, Bulgaria

  • MHAT Alexandrovska EAD

    Sofia, Bulgaria

  • Military Medical Academy

    Sofia, Bulgaria

  • D Rusev

    Sofia, Bulgaria

  • General Hospital for Active Treatment "Stefan Cherkezov"

    Veliko Tarnovo, Bulgaria

  • Dr Kantcho Kostadinov

    Sevileva, Sevilieva, Bulgaria

  • Praxis

    Blankenhain, Germany

  • Praxis

    Fürth, Germany

  • End- und Dickdarm-Zentrum Mannheim

    Mannheim, Germany

  • Gemeinschaftspraxis

    Marl, Germany

  • Practice of Internal Medicine

    Wiesbaden, Germany

  • Kaunas Medical University Clinics

    Kaunas, Lithuania

  • Siauliai Hospital

    Šiauliai, Lithuania

  • UAB Baltic and American Medical and Surgical Clinic

    Vilnius, Lithuania

  • Spitalul Clinic de Urgenta "Prof Dr O Fodor" Cluj

    Cluj Nopoca, Romania

  • Spitalul Clinic de Urgenta "Prof. Dr O Fodor"

    Cluj-Napoca, Romania

  • Spitalul Judetean de Urgenta Deva

    Deva, Romania

  • Institutul de Gastroenterologie si Hepatologie lasi

    Lasi, Romania

  • Spitalul Clinic Judetean de Urgente "Sf.Spiridon" lasi

    Lasi, Romania

  • Cabinet Medical "Dr Lokos" Chirurgie Generala

    Miercurea-Ciuc, Romania

  • Spitalul Clinic Judetean Mures

    Tg Mures, Romania

  • Centrul Medical Tuculanu SRL

    Timișoara, Romania

  • Spitalul Clinic Judetean de Urgenta Timisoara

    Timișoara, Romania

  • Salvo-San-Ciobanca SRL

    Zalău, Romania

  • Hospital Clinico Universitario Lozano Blesa

    Zaragoza, Spain

  • Royal Sussex County Hospital

    Brighton, United Kingdom

  • Derby City General Hospital

    Derby, Derbyshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.